Vesale Bioscience first-round funding

Vésale Bioscience raises a first round of 3M€

A first-round funding of 3 millions euros has been raised by Vésale Bioscience, the spin-out of the Vésale Pharma group which focuses on phagotherapy. In order to increase its financial resources and reach the stock market, the group has hired beLean.net Partner Guillaume de Viron as Head of Finance for the phage therapy division. Co-founder of Univercells, former CFO of MaSTHerCell,[…]

Guillaume CFO

Vésale Bioscience calls on beLean.net to prepare and accelerate its IPO

Vésale Bioscience has hired Guillaume de Viron, Partner at beLean.net, as Chief Financial Officer in order to accelerate its IPO. As CFO, Guillaume de Viron will contribute to Vésale Bioscience, which is currently preparing its fundraising (10+ million €) with the aim of accelerating the production and marketing of phages. Phage therapy is the use of phages,[…]

pocare-platform-img-3 (1)

Initial success for Orgenesis’ POCare Platform

Pharmaceutical companies used to be eager buyers of technology. But in recent years, biotech platforms have benefited from easier access to capital as independent entities, eliminating the need to sell. At the same time, biopharma companies large and small are realizing that building a platform is better than focusing on a single product or production[…]

Brain Innovation Days COVID-19

Rewatch the 3rd Brain Innovation Days Digital Session

Thank you for attending the 3rd Brain Innovation Days Digital Session, Fast-tracking brain innovation in times of COVID-19 last Tuesday! We hope you enjoyed the event as much as we did and found the discussion and insight from our speakers relevant and interesting, looking at COVID-19 from a different angle and discovering potential lessons-learned to be[…]

Imcyse

Imcyse signs licensing agreement with Pfizer

Imcyse raises €21M and opens its capital to its new American partner, Pfizer. Very good news for the Liège-based biotech company Imcyse. Indeed, the biotech has developed an active immunotherapy technology that allows to tackle autoimmune diseases such as multiple sclerosis, type 1 diabetes or rheumatoid arthritis. A licensing agreement has just been signed with[…]

Screenshot 2021-03-31 at 15.23.21

Brain Innovation Days Session #3 – Register Now!

Registration is now open for the upcoming Brain Innovation Days Digital Session, Fast-tracking brain innovation in times of COVID-19, which we are co-organising with the European Brain Council on 27 April at 12:30-14:00. REGISTER NOW The last 14 months have been testing for global health. COVID-19 exposed weaknesses in public health systems’ preparedness to face pandemics and we continue to face[…]

Discussion with PIPRA

Discover how PIPRA aims to prevent Post-Operative Delirium

Listen to the latest edition of Brain Talks, a podcast series under the Brain Innovation Days umbrella Under the overarching theme, “Disrupt and rewire: How brain innovation is changing Europe”, the Brain Innovation Days aim to bring together key opinion leaders and stakeholders from the ever-growing brain innovation ecosystem to create synergies and showcase the importance of[…]

TOP 20 Belgian Biotech Companies 2021

TOP 20 Belgian Biotech Companies 2021

Belgium and its companies at the forefront of the biotechnology industry in Europe Belgium is spearheading the European biotech industry. Meet some of the most successful cases of Belgian biotechnology companies. Belgium is one of the countries that provide the most to the biotech industry in Europe, as it has a total of more than[…]

BIDays#2 - Thank you!

Relive the key moments of the Brain Innovation Days Pitch Competition

We were excited to welcome you to the second digital session of the Brain Innovation Days last week – thank you for joining us! We would like to thank our excellent line-up of guest speakers representing the European Innovation Council, Roche, JLABS – Johnson & Jonhson Innovation, Brain+, Helpilepsy and EIT Health for their valuable insight. Furthermore, thank you to our 9 Pitch Competition[…]

PIPRA icompanion Brain Innovation Days

PIPRA and icompanion, winners of the Brain Innovation Days Pitch Competition!

The Brain Innovation Days hosted its first-ever Pitch Competition during the digital session on January 26. After careful analysis of over 90 applications from start-ups all over Europe, nine finalists went head-to-head to pitch their business in 180 seconds. PIPRA and icompanion were respectively crowned Jury and Public Awards for Best Pitch. Both win a free exhibition booth and free access to our physical event to be held in[…]

1ff4064b-3ef1-4c7d-afbc-46c58a734959

Brain Innovation Days Pitch Competition finalists are announced!

Did you know that the Brain Innovation Days will host its first-ever Pitch Competition during the upcoming digital session on 26 January? After careful analysis of over 90 applications from start-ups all over Europe, nine finalists will go head-to-head to pitch their business in 180 seconds for the chance to be crowned Best Pitch by a jury of highly regarded specialists in the fields of brain science, investment and start-up acceleration. DISCOVER THE[…]

0dfced89-b490-4542-a69a-99d5d518fe8e (1)

Brain Innovation Days Digital Session #2 – Register now!

Happy New Year, Brain Innovators! It’s officially 2021, which means we’re getting closer to the second Brain Innovation Days digital session. Registration is now open for the event to be held on 26 January 2021 at 12:30-14:30. This lunchtime interactive session will fall under the overarching theme, “From innovative ideas to creative brain interventions” and hosts the first ever Brain Innovation Days Pitch Competition, where nine start-ups will go head-to-head to pitch[…]

DSC_1875-copie-scaled2

Novadip receives 9.4 M€ of non-dilutive funding

The Walloon Region Government to support the development of treatments at Novadip with 9.4M€ of non-dilutive funding Novadip Biosciences, a clinical-stage company developing treatments to regenerate damaged tissues in patients with significant unmet medical needs, has announced that the US Food and Drug Administration (FDA) has granted the designation of Rare Pediatric Disease and Orphan[…]

1600335902672

OUAT! raises 500k€ with the Innovation Fund

  OUAT! recently raised 500k€ with the Innovation Fund. The capital infusion will support the further development of HakoBio and the roll out of the software to new clients. OUAT! aims to facilitate the digital transformation of the life sciences industry. In increasingly intelligent and connected factories, OUAT! enables the men and women of the biopharmaceutical industry to achieve[…]

1608194538472-square-2

Univercells raises €70 million in Series C Financing

Univercells Holding recently raises €70 million with two rounds of capital increase with new investors. The capital infusion will support the development of GMP facilities and the capacity to foster distributed manufacturing and supply of biologics. Univercells recently completed their Series C second close, bringing the total raised to €70 million. The financing, which was over-subscribed,[…]

1608040470311

Brain Innovation Days Digital Session #2 – Save the date!

The European Brain Council and beLean.net are pleased to invite you to the second Brain Innovation Days digital session, to be held on 26 January 2021 at 12:30-14:30. This lunchtime interactive session will fall under the theme Creative Brain Interventions and will host the first Brain Innovation Days Pitch Competition, where a number of start-ups will go head-to-head to pitch their business for the chance to win Best[…]

George Soros

Univercells, beneficiary of financial support from major investors

Many large investors have already set their sights on the Walloon company Univercells. Among them stands out the American billionaire George Soros; famous financier and philanthropist at the age of 90, Adjuvant Capital; a fund linked to the Bill Gates galaxy, the federal government through SFPI, and the Walloon government through SRIW. Bill Gates, as[…]